Howard I. Scher
0000-0002-6791-9324
Publication & Citation Trends
Publications
0 total
Can Ultra-Hypofractionated Stereotactic Radiation After Radical Prostatectomy Cut Time on Treatment or Are the Data Not Sharp Enough?
Cited by 0
Semantic Scholar
Abstract P2-01-25: Circulating tumor DNA clearance by neoadjuvant chemotherapy or breast surgery detected using an ultrasensitive ctDNA MRD assay in early breast cancer
Cited by 0
Semantic Scholar
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.
Cited by 0
Semantic Scholar
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.
Cited by 2
Semantic Scholar
Personalized circulating tumor DNA for minimal residual disease and dynamic assessment in patients undergoing neoadjuvant chemotherapy for breast cancer: Preliminary analysis from MSK-LINC.
Cited by 0
Semantic Scholar
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy OA
Cited by 7
Semantic Scholar
Impact of PARP Inhibitor and Platinum Therapy on Clonal Hematopoiesis OA
Cited by 1
Semantic Scholar
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer OA
Cited by 81
Semantic Scholar
Breast cancer, early stage OA
Cited by 44
Semantic Scholar
Research Topics
Prostate Cancer Treatment and Research
(918)
Radiopharmaceutical Chemistry and Applications
(328)
Prostate Cancer Diagnosis and Treatment
(179)
Cancer Genomics and Diagnostics
(174)
Cancer, Lipids, and Metabolism
(166)
Affiliations
Université Paris-Sud
University of Vermont
University of North Carolina at Chapel Hill
Tulane University
University of Southern California